Clinical trials: Olaparib, completed
Pancreatic Cancer
Efficacy and Safety of PARPi to Treat Pancreatic Cancer
This is an open label, single arm, phase II trial of Olaparib for (PDAC) pancreatic ductal adenocarcinoma patients with BRCAness (breast cancer gene). All study subjects will receive Olaparib in a dose of 300 mg p.o twice daily.
- Trial name
- 10 (NCT02511223)
- Testing
- OLAPARIB
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Sheba Medical Center
Gastric Cancer
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line…
- Trial name
- NCT01924533
- Testing
- Olaparib, Paclitaxel
- Where
- 57 sites in China, Japan and 2 more
- Volunteers
- 525 people
- Sponsor
- AstraZeneca
Prostate Cancer
Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
Despite recent advances in the treatment of Castrate-Resistant Prostate Cancer (CRPC), there remains an unmet medical need to identify and optimise additional treatment for those patients with early prostate cancer who are at…
- Trial name
- CaNCaP03 (NCT02324998)
- Testing
- Olaparib, Degarelix
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Ovarian Cancer, Breast Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs.
- Trial name
- NCT01623349
- Testing
- BKM120 and Olaparib, BYL719 and Olaparib
- Where
- 5 sites in United States
- Volunteers
- 118 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer
Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
Epithelial ovarian cancer harbours 20% Breast Cancer gene (BRCA)1/2 mutations independently of family history. Poly ADP ribose polymerase (PARP) inhibitors (PARPi) have shown clinical activity among patients with homologous…
- Trial name
- NCT03470805
- Testing
- Olaparib
- Where
- 16 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Cancer
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious adverse events such as pancytopenia. Today, data about pancytopenia are scarce.
- Trial name
- NCT04774627
- Testing
- PARP inhibitor
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Caen
Cancers With DNA Repair-Deficiency
Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
Evaluation of the efficacy of the combination of olaparib and trabectedin in adult patients with locally advanced/metastatic solid tumors that failed standard treatment and whose molecular sequencing tumor profiles show…
- Trial name
- NCT-PMO-1603 (NCT03127215)
- Testing
- Olaparib, Physician's choice, Trabectedin
- Where
- 9 sites in Germany
- Volunteers
- 102 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Soft Tissue Sarcoma, Bone Tumor
Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
This is a Phase 1b, multi-site, open-label, non-randomized clinical trial evaluating the safety, tolerability, and pharmacokinetics of escalating doses of olaparib and trabectedin in patients with unresectable advanced/metastatic…
- Trial name
- TOMAS (NCT02398058)
- Testing
- trabectedin, olaparib
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Italian Sarcoma Group
Metastatic Castration-resistant Prostate Cancer
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once…
- Trial name
- NCT01972217
- Testing
- Olaparib, Abiraterone, Prednisone or prednisolone
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
SCLC
Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]
This study is a single arm, multi-center phase II study of AZD6738 and olaparib combination therapy in patients with relapsed small cell lung cancer (SCLC) as a second or third line chemotherapy.
- Trial name
- NCT03428607
- Testing
- AZD6738, Olaparib
- Where
- South Korea
- Volunteers
- 26 people
- Sponsor
- Samsung Medical Center
Solid Tumours
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
This is an open-label 2-part Phase I study in patients with advanced solid tumours. Part A of the study (mandatory) will assess the effect of olaparib on the pharmacokinetics (PK) of anastrozole, letrozole and tamoxifen and vice…
- Trial name
- NCT02093351
- Testing
- Olaparib, Tamoxifen, Anastrozole
- Where
- 14 sites in Belgium, Denmark and 3 more
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Breast Cancer
PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
Study involves surgery for cytoreduction or laparoscopy to determine if you are a candidate for tumor debulking or a tissue biopsy. Following this surgery you will receive chemotherapy.
- Trial name
- NCT04041128
- Testing
- Lynparza
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Healthy Participants
Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects
This Study is a Randomized, Open-Label, 2-formulation, Single-Dose, 2-Period Crossover Bioequivalence Study with a washout period of 7 days.
- Trial name
- NCT06360445
- Testing
- Olaparib Tablet test formulation 100mg, Olaparib Tablet reference formulation 100mg, Olaparib Tablet test formulation 150mg
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Breast Neoplasms
Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer
The purpose of the study is to see if the drug KU-0059436 (olaparib) is effective and well tolerated in treating participants with measurable breast cancer gene (BRCA)1- or BRCA2-positive advanced breast cancer and for whom no…
- Trial name
- ICEBERG 1 (NCT00494234)
- Testing
- Olaparib
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Glioblastoma, Glioblastoma Multiforme
Study of Pamiparib in Newly Diagnosed and rGBM
This is an open-label, single-center Phase 0/2 study that will enroll up to 30 participants with newly diagnosed (N=12) and recurrent glioblastoma (N=18).
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
- Trial name
- NCT04614909
- Testing
- Pamiparib, Olaparib, Radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Nader Sanai
Esophagogastric Adenocarcinoma
Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma
This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity of a first-line therapy consisting of induction chemotherapy plus pembrolizumab (12 weeks of mod.
- Trial name
- NCT05268510
- Testing
- Pembrolizumab, Olaparib, mFOLFOX-6
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Solid Malignancies
Open Label, Dose Escalation Phase I Study of AZD2281
The purpose of the study is to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies
- Trial name
- NCT00572364
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor)
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Breast Cancer
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
Background: Olaparib is an experimental anti-cancer drug that is part of a class of drugs called PARP inhibitors. PARP is a protein that is involved in repairing DNA damage, but it may also encourage precancerous cells to develop…
- Conditions
- Ovarian Cancer, Breast Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01237067
- Testing
- Carboplatin, Olaparib
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, GastroEsophageal Cancer
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
This study is an open-label, phase II study with a safety lead-in to assess the response rate of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination olaparib/pembrolizumab in patients with…
- Trial name
- NCT05379972
- Testing
- Pembrolizumab, Olaparib, Stereotactic Body Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Gastric Cancer
Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
To assess the efficacy of olaparib when given in combination with paclitaxel compared with paclitaxel alone as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress…
- Trial name
- NCT01063517
- Testing
- olaparib, paclitaxel
- Where
- 7 sites in South Korea
- Volunteers
- 124 people
- Sponsor
- AstraZeneca